Abstract
Cardiogenic shock (CS) is a complex clinical syndrome with various etiologies and clinical presentations. Despite advances in therapeutic options, mortality remains high, and clinical trials in the field are complicated in part by the heterogeneity of CS patients. More individualized targeted therapeutic approaches might improve outcomes in CS, but their implementation remains challenging. The present review discusses current and emerging machine learning-based approaches, including unsupervised and supervised learning methods that use real-world clinical data to individualize therapeutic strategies for CS patients. We will discuss the rationale for each approach, potential advantages and disadvantages, and how these strategies can inform clinical trial design and management decisions.